Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
07 apr 2016 - 16:04
Statutaire naam
Galapagos NV
Titel
Galapagos and MorphoSys initiate Phase 1 study in joint antibody program MOR106
Bericht
Mechelen, Belgium and Martinsried/Munich, Germany; 7 April 2016 - Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that dosing of MOR106, a first-in-class candidate human monoclonal antibody, has been initiated in healthy volunteers in a Phase 1 study. MOR106 was jointly discovered by Galapagos and MorphoSys under their collaboration, and has a novel mode of action with potential application in inflammation.
Datum laatste update: 31 maart 2026